News

MediGene Obtains Additional US Patent Protection

SHOW RELEASE

MediGene AG Reports Financial Results for First Six Months of 2010: Continuing Increase in Total Revenue, Significant Reduction of Loss

SHOW RELEASE

Change of date: 6-month 2010 financial report on August 5, 2010

SHOW RELEASE

MediGene sells full European rights for Eligard® to Astellas for EUR 25 million and ongoing royalties

SHOW RELEASE

MediGene reports additional phase II results of EndoTAG(TM)-1 for the treatment of triple receptor-negative breast cancer

SHOW RELEASE

MediGene continues the global licensure of Veregen® through agreements with GC Rise in China and JS Bio Pharm in South Korea

SHOW RELEASE

MediGene AG reports on first quarter of 2010:total revenue increased - cost constant

SHOW RELEASE

MediGene publishes first, preliminary results obtained in a phase II clinical trial of EndoTAGTM-1 for the treatment of triple receptor-negative breast cancer

SHOW RELEASE

New CFO Arnd Christ to take up position at MediGene in April

SHOW RELEASE

MediGene AG divests Oncolytic Herpes Simplex Viruses (oHSV) program to Catherex, Inc.

SHOW RELEASE